Internalizing ErbB2 antibodies
US9388244B2 · kind B2 · utility
1Cited by
8References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2015 |
| Grant date | Jul 12, 2016 |
| Priority date | — |
| Expiry date | Feb 20, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/812
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.